Puisset F - Search Results

1

Investigating the clinical impact of dose-banding for weekly paclitaxel in patients with breast cancer: A retrospective and monocentric study.

Puisset F, Le Louedec F, Dalenc F, Verguet L, De Maio E, Lacaze JL, Montastruc M, Ung M, Vinson C, Perriat S, Pacher S, Chatelut E, Koning MW. Puisset F, et al. Br J Clin Pharmacol. 2023 Jul;89(7):2283-2294. doi: 10.1111/bcp.15702. Epub 2023 Mar 20. Br J Clin Pharmacol. 2023. PMID: 36854898 Free article.

2

Dexamethasone as a probe for docetaxel clearance.

Puisset F, Chatelut E, Dalenc F, Busi F, Cresteil T, Azéma J, Poublanc M, Hennebelle I, Lafont T, Chevreau C, Roché H. Puisset F, et al. Cancer Chemother Pharmacol. 2004 Sep;54(3):265-72. doi: 10.1007/s00280-004-0823-0. Epub 2004 May 5. Cancer Chemother Pharmacol. 2004. PMID: 15133628 Clinical Trial.

3

Dexamethasone as a probe for vinorelbine clearance.

Puisset F, Dalenc F, Chatelut E, Cresteil T, Lochon I, Tisnes P, Roché H. Puisset F, et al. Br J Clin Pharmacol. 2005 Jul;60(1):45-53. doi: 10.1111/j.1365-2125.2005.02384.x. Br J Clin Pharmacol. 2005. PMID: 15963093 Free PMC article. Clinical Trial.

4

Dexamethasone as a probe for CYP3A4 metabolism: evidence of gender effect.

Puisset F, Chatelut E, Sparreboom A, Delord JP, Berchery D, Lochon I, Lafont T, Roché H. Puisset F, et al. Cancer Chemother Pharmacol. 2007 Jul;60(2):305-8. doi: 10.1007/s00280-006-0385-4. Epub 2006 Nov 24. Cancer Chemother Pharmacol. 2007. PMID: 17124593

5

Clinical pharmacodynamic factors in docetaxel toxicity.

Puisset F, Alexandre J, Treluyer JM, Raoul V, Roché H, Goldwasser F, Chatelut E. Puisset F, et al. Br J Cancer. 2007 Aug 6;97(3):290-6. doi: 10.1038/sj.bjc.6603872. Epub 2007 Jun 26. Br J Cancer. 2007. PMID: 17595656 Free PMC article. Clinical Trial.

6

Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents.

Chatelut E, White-Koning ML, Mathijssen RH, Puisset F, Baker SD, Sparreboom A. Chatelut E, et al. Among authors: puisset f. Br J Cancer. 2012 Sep 25;107(7):1100-6. doi: 10.1038/bjc.2012.357. Epub 2012 Aug 28. Br J Cancer. 2012. PMID: 22929884 Free PMC article.

7

Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease.

Puisset F, White-Koning M, Kamar N, Huart A, Haberer F, Blasco H, Le Guellec C, Lafont T, Grand A, Rostaing L, Chatelut E, Pourrat J. Puisset F, et al. Br J Clin Pharmacol. 2013 Nov;76(5):734-40. doi: 10.1111/bcp.12098. Br J Clin Pharmacol. 2013. PMID: 23432476 Free PMC article. Clinical Trial.

8

Standardization of chemotherapy and individual dosing of platinum compounds.

Puisset F, Schmitt A, Chatelut E. Puisset F, et al. Anticancer Res. 2014 Jan;34(1):465-70. Anticancer Res. 2014. PMID: 24403502 Review.

9

The scientific basis of body surface area-based dosing.

Chatelut E, Puisset F. Chatelut E, et al. Among authors: puisset f. Clin Pharmacol Ther. 2014 Apr;95(4):359-61. doi: 10.1038/clpt.2014.7. Clin Pharmacol Ther. 2014. PMID: 24646485 No abstract available.

10

Simultaneous monitoring of pazopanib and its metabolites by UPLC-MS/MS.

Paludetto MN, Puisset F, Le Louedec F, Allal B, Lafont T, Chatelut E, Arellano C. Paludetto MN, et al. Among authors: puisset f. J Pharm Biomed Anal. 2018 May 30;154:373-383. doi: 10.1016/j.jpba.2018.03.013. Epub 2018 Mar 9. J Pharm Biomed Anal. 2018. PMID: 29571135

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

36 results

Search Page

Filters